Építés alatt – nem éles oldal
Belépés
Résztvevőt keresFázis nélkül

Anti CD19/BCMA CAR Gene Therapy for Relapsed/Refractory Immune Thrombocytopenia

A legfontosabb adatok

Ki végzi
Anhui Provincial Hospital
Hol
Kína1 helyszín, 1 országbanVálassz országot a helyszínekhez
Azonosító
Állapot
Toboroz
Résztvevők
18 fő, tervezett
Kezdés
2025. aug. 16.
Várható befejezés
2029. jún. 30.
A vizsgálat típusa
Beavatkozással járó
A vizsgált kezelések
  • Anti-CD19/BCMA CAR gene vector injection will be injected intravenously on a one-time basis.
A regiszteradat frissítve
2025. augusztus 8.

Ki vehet részt

MI-összefoglaló

A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.

The trial is looking for adults with primary immune thrombocytopenia (ITP) that came back or did not respond to earlier treatment. They will get a single infusion of an anti-CD19/BCMA CAR gene vector into a vein.

Életkor
18 years and older
Nem
All sexes
A betegség stádiuma
Primary ITP diagnosed at least 6 months ago. Platelet count below 30×10^9/L within 48 hours before joining. Bone marrow test shows normal or increased megakaryocytes (platelet-making cells). ECOG performance status 2 or lower.
Korábbi kezelés
Must have had second-line ITP treatment, such as thrombopoietin receptor agonists (eg, eltrombopag, romiplostim) and/or rituximab. That treatment did not work, the disease came back after it, or platelets were hard to keep up after stopping TPO agonists.
Biomarker vagy leletérték
Positive anti-platelet glycoprotein autoantibodies (such as GPIIb/IIIa).

A részvétel fő kizáró okai

  • Low platelets caused by another disease, such as myelodysplastic syndrome, aplastic anemia or thrombotic thrombocytopenic purpura
  • Serious heart disease, such as NYHA class III to IV heart failure or a heart attack within 6 months
  • Cancer within 3 years before screening, with some exceptions
  • Active hepatitis B or C, HIV, or a positive syphilis test
  • Pregnancy or breastfeeding, or deep vein clot or lung clot within the past 6 months

A regiszter feltételei, szó szerint

Mind a 2 feltétel megnézéseKevesebb

Ki vehet részt

  • 1. Age≥ 18 years old, regardless of gender. 2. Clinical diagnosis of primary immune thrombocytopenia for at least 6 months, platelet count < 30×10\^9/L within 48 hours before participating in the study; Positive anti-platelet glycoprotein autoantibodies (such as GPIIb/IIIa). 4. Prior second-line ITP therapy (first-line treatment includes: corticosteroids or immunoglobulins; Second-line therapies include thrombopoietin receptor agonists (eg, eltrombopag, romiplostim) and/or rituximab, but are ineffective (platelet count < 30×10\^9/L after treatment, or platelet count does not increase twice as much as baseline, or there is bleeding), or relapse after effective treatment (platelet count falls below 30×109/L after effective treatment, or falls below baseline, or bleeding symptoms) or is difficult to maintain after discontinuation of TPO agonists; Bone marrow examination shows megakaryocytosis or normal. 6. Basic normal functions of important organs:Echocardiography shows an ejection fraction of ≥50% and no significant abnormalities on ECG.Creatinine clearance (CrCl) (Cockcroft-Gault formula) ≥ 30 mL/min.Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3.0 × upper limit of normal (ULN).Total bilirubin (TBIL) and alkaline phosphatase (AKP or ALP) ≤ 2.0× ULN (Gilbert's syndrome ≤3.0×ULN).Absolute lymphocyte count (ALC) ≥ 0.5×10\^9/L; Absolute neutrophil count (ANC) ≥1×10\^9/L; Hemoglobin (Hb) ≥ 60 g/L; Platelet count ≥ 10×10\^9/L.Oxygen saturation > 92%.ECOG performance status ≤2 7. Males and women of childbearing potential must agree to use effective contraception from the time of signing the informed consent form until 1 year after the use of the study drug. Women of childbearing potential must have a negative blood pregnancy test at screening and prior to drug infusion and must not be breastfeeding

Ki nem vehet részt

  • 1. Thrombocytopenia caused by myelodysplastic syndrome, early aplastic anemia, atypical aplastic anemia, thrombotic thrombocytopenic purpura, etc; During the screening period, bone marrow examination showed myelofibrosis MF≥2 (European consensus scoring standard Thieleja 2005) or bone marrow examination showed the presence of a primary disease other than ITP that can lead to thrombocytopenia; History of hypersensitivity to any component of the therapeutic medication. 4. Major organs: NYHA class III to IV congestive heart failure. Myocardial infarction or coronary artery bypass grafting (CABG) or coronary artery stent implantation within 6 months. Ventricular arrhythmias, or history of unexplained syncope (excluding vasovagal syncope or dehydration). History of severe non-ischemic cardiomyopathy; Malignant disease within 3 years prior to screening, except for the following: malignant disease that has been curatively treated before enrollment and has no known active disease for 3 years ≥; or well-treated non-melanoma skin cancer with no evidence of disease; Symptomatic deep vein thrombosis or pulmonary embolism within the past 6 months or currently requiring anticoagulation; Participated in other interventional clinical studies within 1 month prior to screening; Vaccination of live attenuated vaccine within 4 weeks prior to screening. 9. Stroke or seizure within 6 months prior to signing the ICF (excluding old lacunar cerebral infarction); Positive for hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb) and peripheral blood hepatitis B virus (HBV) DNA titer test exceeds the normal range; Hepatitis C virus (HCV) antibody is positive and the hepatitis C virus (HCV) RNA titer in peripheral blood exceeds the normal range; positive for human immunodeficiency virus (HIV) antibodies; Positive syphilis test; Known history of bone marrow stem cell disease 12. Other conditions that the investigators consider unsuitable to participate in the study

Ennek a vizsgálatnak nincs helyszíne itt: Egyesült Államok.

Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.

A vizsgálatról

Mit akar kideríteni a vizsgálat

This is an open label, single-site, dose-escalation study in up to 18 participants with treatment of relapsed and refractory immune thrombocytopenia. This study aims to evaluate the safety and efficacy of the treatment with an Anti- CD19/BCMA CAR gene vector injection

A vizsgálat csoportja

  • Experimental: Anti-CD19/BCMA CAR gene vector injectionA vizsgált kezelés

    Arm Description: Intravenous infusion of Anti-CD19/BCMA CAR gene vector injection

    Kezelés: Anti-CD19/BCMA CAR gene vector injection will be injected intravenously on a one-time basis.

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
An Exploratory Clinical Study of Anti-CD19/BCMA CAR Gene Vector Injection (LCAR1901) for the Treatment of Relapsed and Refractory Immune Thrombocytopenia
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
A regiszteradat frissítve
2025. augusztus 8.